These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 33870531)

  • 1. Baricitinib: From Rheumatoid Arthritis to COVID-19.
    Assadiasl S; Fatahi Y; Mosharmovahed B; Mohebbi B; Nicknam MH
    J Clin Pharmacol; 2021 Oct; 61(10):1274-1285. PubMed ID: 33870531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
    Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
    Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib set to join the Covid-19 therapeutic arsenal?
    Gudu T; Stober C; Cope AP; Cheriyan J; Galloway J; Wilkinson IB; Kostapanos M; Jayne D; Hall F
    Rheumatology (Oxford); 2021 Apr; 60(4):1585-1587. PubMed ID: 33502499
    [No Abstract]   [Full Text] [Related]  

  • 5. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
    Harigai M; Honda S
    Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of baricitinib in patients with rheumatoid arthritis.
    Honda S; Harigai M
    Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
    [No Abstract]   [Full Text] [Related]  

  • 7. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
    Collotta D; Hull W; Mastrocola R; Chiazza F; Cento AS; Murphy C; Verta R; Alves GF; Gaudioso G; Fava F; Yaqoob M; Aragno M; Tuohy K; Thiemermann C; Collino M
    Mol Metab; 2020 Sep; 39():101009. PubMed ID: 32413585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
    Mogul A; Corsi K; McAuliffe L
    Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
    [No Abstract]   [Full Text] [Related]  

  • 10. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
    Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
    Front Immunol; 2021; 12():704526. PubMed ID: 34497607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.
    Mendes JT; Balogh EA; Strowd LC; Feldman SR
    Expert Opin Pharmacother; 2020 Jun; 21(9):1027-1033. PubMed ID: 32208940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
    Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M;
    EMBO Mol Med; 2020 Aug; 12(8):e12697. PubMed ID: 32473600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib.
    Anjara P; Jiang M; Mundae M
    Clin Rheumatol; 2020 Feb; 39(2):613-614. PubMed ID: 31782014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.
    Sakai H; Kamuro H; Tokunoh N; Izawa T; Tamiya S; Yamamoto A; Tanaka S; Okuzaki D; Ono C; Matsuura Y; Okada Y; Yoshioka Y; Fujio Y; Obana M
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F931-F941. PubMed ID: 38634132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
    Hoang TN; Pino M; Boddapati AK; Viox EG; Starke CE; Upadhyay AA; Gumber S; Nekorchuk M; Busman-Sahay K; Strongin Z; Harper JL; Tharp GK; Pellegrini KL; Kirejczyk S; Zandi K; Tao S; Horton TR; Beagle EN; Mahar EA; Lee MYH; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Delmas OM; Wang S; Cooney KA; Sayegh MN; Wang L; Filev PD; Weiskopf D; Silvestri G; Waggoner J; Piantadosi A; Kasturi SP; Al-Shakhshir H; Ribeiro SP; Sekaly RP; Levit RD; Estes JD; Vanderford TH; Schinazi RF; Bosinger SE; Paiardini M
    Cell; 2021 Jan; 184(2):460-475.e21. PubMed ID: 33278358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
    Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
    Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The beneficial effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis: Preliminarily data from single center-based observational study for 24 weeks.
    Kim SK; Jung UH; Kim JW; Choe JY
    Medicine (Baltimore); 2021 Jul; 100(30):e26739. PubMed ID: 34397713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
    Taylor PC; Weinblatt ME; Burmester GR; Rooney TP; Witt S; Walls CD; Issa M; Salinas CA; Saifan C; Zhang X; Cardoso A; González-Gay MA; Takeuchi T
    Arthritis Rheumatol; 2019 Jul; 71(7):1042-1055. PubMed ID: 30663869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.